Neurocrine CRO gets 4,483-share stock grant

NBIX’s Chief Regulatory Officer received common stock from vested performance units, with part of the shares withheld to cover taxes and no market sale reported.

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Regulatory Officer Ingrid Delaet received a grant of 4,483 shares of common stock on September 11, 2026 upon certification of a performance metric tied to previously awarded performance restricted stock units (PRSUs). On the same date, 2,419 shares were withheld by the company at a price of $156.22 per share to satisfy tax withholding requirements on the PRSU vesting, and the filing specifies that no shares were sold. No Rule 10b5-1 trading plan was reported for these transactions.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Delaet Ingrid

Role Chief Regulatory Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	4,483	$0.00	$0.00
Tax Withholding	Common Stock F2	2,419	$156.22	$378K

Holdings After Transaction: Common Stock — 18,289 shares (Direct)

Footnotes (2)

1. F1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
2. F2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Key Figures

Shares acquired from PRSU vesting: 4,483 shares Shares withheld for taxes: 2,419 shares Withholding price per share: $156.22 per share +1 more

4 metrics

Shares acquired from PRSU vesting 4,483 shares Grant of common stock upon certification of a performance metric on September 11, 2026

Shares withheld for taxes 2,419 shares Withheld by the company to satisfy tax withholding on PRSU vesting

Withholding price per share $156.22 per share Price used for the 2,419 shares withheld to cover tax obligations

PRSU performance metric certification date September 11, 2026 Date on which achievement of one performance metric was certified, triggering vesting

Key Terms

performance restricted stock units (PRSUs), tax withholding requirements, vesting

3 terms

performance restricted stock units (PRSUs) financial

"previously granted performance restricted stock units (PRSUs) that vest upon the achievement"

tax withholding requirements financial

"Shares withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements"

vesting financial

"to satisfy tax withholding requirements on vesting of PRSUs"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NBIX’s Chief Regulatory Officer acquire in this Form 4 filing?

The Chief Regulatory Officer, Ingrid Delaet, acquired 4,483 shares of NBIX common stock on September 11, 2026, when a performance metric tied to previously granted performance restricted stock units (PRSUs) was certified as achieved.

Why were 2,419 NBIX shares disposed of in this Form 4?

The filing states that 2,419 shares of NBIX common stock were withheld by the company at $156.22 per share solely to satisfy tax withholding requirements on vesting of PRSUs, and that no shares were sold.

Were the NBIX Form 4 transactions by Ingrid Delaet made under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox is not checked, and there is no footnote indicating that the transactions were made pursuant to any Rule 10b5-1 trading plan.

What performance condition triggered the NBIX PRSU share grant?

The filing explains that the 4,483 shares relate to previously granted PRSUs that vest upon achieving certain performance metrics, and that the achievement of one metric was certified on September 11, 2026, triggering this vesting.

Did the NBIX insider actually sell any shares in the market in this Form 4?

No. A footnote clarifies that the 2,419 shares were withheld by Neurocrine Biosciences to satisfy tax withholding on PRSU vesting and that no shares were sold in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 05:04 PM Accepted by SEC EDGAR 09/15/2026 - 05:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Delaet Ingrid

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		A(1)		4,483	A	$0	20,708	D
Common Stock	09/11/2026		F(2)		2,419	D	$156.22	18,289	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)